###### Strengths and limitations of this study

-   This research was conducted in three open populations from different provinces of Spain.

-   Mitochondrial respiratory chain single nucleotide polymorphisms (SNP) analysis by SNPlex genotyping method overcomes some of the limitations of genome- wide association studies.

-   One of the limitations of this study is the reduced size of the populations used

-   Despite the limited number of individuals in this study, the statistical power is sufficient for the number of analysed SNPs.

-   Results from this study are promising and should be validated by larger sample sizes.

Introduction {#s1}
============

Obesity is a metabolic disorder consisting of excess body fat accumulation. Obesity prevalence has been increasing during the last decades in Western societies, becoming one of the most important public health problems due to its causal relationship with several chronic diseases such as insulin resistance, cardiovascular disease and type 2 diabetes mellitus (T2DM).[@R1]

Susceptibility to obesity is determined by environmental and genetic factors. Although rising obesity prevalence is triggered by lifestyle changes, the risk of developing obesity has an important genetic component, which has been examined in numerous studies.[@R2] Rare mutations in genes encoding for appetite-regulating proteins, such as leptin (*LEP*) and its receptor (*LEPR*), melanocortin-4 receptor (*MC4R*) and pro-opiomelanocortin (*POMC*), have been shown to cause severe early-onset obesity.[@R5] Genome-wide association studies (GWAS) have identified common polymorphisms located in, or near to, 97 loci, mostly expressed in the central nervous system.[@R6] However, it is also suggested that, due to limitations of GWAS, there are around 250 common variants with a similar effect to those previously described that remain to be identified.[@R8]

The study of target genes or genes involved in a particular physiological pathway is a potential approach to identify genetic variants with roles in complex traits. The mitochondrial respiratory chain (MRC) is a biological system involved in carbohydrate and lipid metabolism through oxidative phosphorylation. MRC produces the proton gradient needed for ATP synthesis and is composed of four large complexes (I to IV) that transport electrons from donors (NADH at complex I, FADH2 at complex II) to acceptors. Finally, electrons in complex IV are conducted to the last acceptor, the molecular oxygen.[@R11] Mitochondrial oxidative capacity dysfunction in liver, muscle or adipose tissue could contribute to the intracellular accumulation of fatty acids observed in obesity.[@R12] Insulin resistance has been associated with lower mitochondria activity at rest.[@R14] This may be the result of inherited defects in genes coding MRC proteins.

Mutations of MRC genes resulting in loss of function have been reported to produce major disability-causing diseases.[@R15] In addition, studies on their impact on energy efficiency and expenditure have shown an association with the risk of developing obesity.[@R12] Studies have also shown that obesity affects the function of mitochondria, leading to mitochondrial dysfunction.[@R22] Mitochondrial dynamics play a role in metabolism and obesity: *MFN2*, a gene coding for a GTPase in the outer mitochondrial membrane is involved in mitochondrial fusion, regulating the operation of the mitochondrial network in skeletal muscle. When *MFN2* is repressed, glucose oxidation and mitochondrial membrane potential are impaired.[@R23] It has been shown that expression of *MNF2* is repressed in obese patients compared with lean.[@R23] Furthermore, polymorphisms in MRC genes, or others related to its regulation, have been related to obesity in different populations.[@R23]

The aim of this study was to find associations between MRC nuclear genes, body mass index (BMI) and obesity in three different Spanish studies in the general population.

Materials and methods {#s2}
=====================

Sample populations {#s2a}
------------------

We independently analysed three general Spanish populations originally recruited for the study of cardiovascular risk factors and cardiovascular disease development: HORTEGA (1502 subjects collected from 2004 to 2005), PIZARRA (988 individuals, collected from 2009 and 2010) and SEGOVIA (1239 subjects, collected between 2000 and 2003).[@R26] The HORTEGA sample involves subjects from the Valladolid area (Northwestern Spain). The PIZARRA sample comprises subjects from Pizarra, a town in the Malaga province (Andalusia, Southern Spain). The SEGOVIA sample studied subjects from the Segovia Province (Centre of Spain). These three populations were recruited to identify cardiovascular risk factors in the general population as an overall goal. Individuals were randomly selected and invited to participate. Exclusion criteria were any concomitant disease or condition that prevented them from answering a survey, or donating a sample or that would influence the collection of reliable information. The study was approved. All patients provided informed written consent to take part in the investigations. The research was carried out according to the Ethical Principles of the World Medical Association (Declaration of Helsinki).

Demographic data and anthropometric parameters were collected following standard procedures. Presence of obesity, hypertension (HTN) and type 2 diabetes mellitus (T2DM) was recorded. BMI was calculated by dividing weight in kilograms by height in metres squared. Obesity, HTN and T2DM were defined using the WHO criteria (<http://www.who.int>). Briefly, obesity was diagnosed with a BMI \>30 kg/m^2^, overweight as BMI between 25.0 and 29.9 kg/m^2^ and normal weight as BMI [\<]{.ul}24.9 kg/m^2^. HTN was defined by systolic and diastolic blood pressure above 140 or 90 mm Hg, respectively. T2DM was defined by fasting plasma glucose ≥126 mg/dL or 2-hour plasma glucose ≥200 mg/dL. Previous diagnosis of T2DM or HTN and detection of the disease at the moment of sample collection were recorded. Missing data for parameters regarding this work (expressed as HORTEGA missing data/PIZARRA missing data/SEGOVIA missing data) were 58/58/6 for BMI and 1/85/63 for glucose.

We have calculated the statistical power for our three samples independently (minor allele frequency (MAF) \>0.10, genotype relative risk (1.5)), number of obese and non-obese and prevalence of obesity in each of the populations. Furthermore, the statistical power was over 85% for these conditions in all populations and it increases for increased allele frequency (<http://csg.sph.umich.edu/abecasis/cats/gas_power_calculator/index.html>).

Genotyping methods {#s2b}
------------------

### Gene and single nucleotide polymorphisms selection {#s2b1}

Forty-eight single nucleotide polymorphisms (SNPs) of chromosomal genes coding for MRC proteins were selected for genotyping. Selection was performed based on the following considerations: functionality (previously described or possible effect), MAF ≥1%, representation of genetic variability of the whole gene (HapMap polymorphisms) and spacing along the gene. Most important variants described in the literature were included. Details of genes and SNPs included are shown as online [supplemental material (table 1S)](#SP1){ref-type="supplementary-material"}.
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### Genotyping procedure {#s2b2}

Venous blood samples were collected in tubes containing EDTA. DNA was isolated by standard commercial procedures (Chemagic Magnetic Separator from Chemagen, Baesweiler, Germany). DNA was quantified and diluted to a final concentration of 100 ng/µL.

SNPlex (Applied Biosystems, Foster City, California, USA) was used for genotyping, following the manufacturer's guidelines. SNPlex is a genotyping system based on oligonucleotide ligation assay/PCR technology that analyses 48 SNPs. Those SNPs were chosen as explained above.

Statistical analysis {#s2c}
--------------------

Statistical analyses were performed using SPSS V.19 and SNPStats software.[@R29]

Chi-squared test and variance analysis were used to compare quantitative and categorical variables between groups in order to assess general characteristics of the studied populations. P values \<0.05 were considered significant.

When analysing for associations between SNPs and obesity traits in the three populations, 11 out of the 48 SNPs were excluded from the study because they did not fulfil the Hardy-Weimberg equilibrium, had low frequency or were not detectable by the genotyping procedure. Hardy-Weimberg test indicated no loss of heterozygosity in the analysed populations for these SNPs. The Bonferroni correction cut-off to assess significant associations was calculated for the 37 remaining SNPs. Those polymorphisms associated in at least one of the three populations and showing the same tendency in the remaining ones, or results with p values near the nominal cut-off point in the three studies (p\<0.05), were also analysed in the 3729 total combined subjects from the three populations. For these analyses, multivariate logistic regression under codominant model was performed and, if applicable, dominant, recessive or additive models were used. For categorical variables, adjusted OR were assessed with 95% CI. The association between polymorphisms and BMI values was examined using analysis of covariance. All p values were two-sided. All results were obtained after adjustment for age and gender, and p values \<0.05 were considered significant.

Patient and public involvement {#s2d}
------------------------------

Patients and public were not actively involved in this research. They were informed regarding the research goals, protocol development and parameters to be measured before starting the study. If appropriate, they were informed regarding results.

Results {#s3}
=======

Characteristics of the studied populations {#s3a}
------------------------------------------

General characteristics of the studied populations are summarised in [table 1](#T1){ref-type="table"}. Age, gender and BMI varied between the three populations. There were differences in obesity and T2DM percentage: obesity prevalence was 17%, 26% and 33% for Hortega, Segovia and Pizarra studies, respectively, while T2DM prevalence was 7.6%, 10.2% and 19.6%. Increased means of age correspond to the age structure of our population. BMI means correspond to overweight values, what is in agreement with the fact that obesity is increasing in Western societies (WHO).

###### 

General features of Hortega, Pizarra and Segovia patients considered individually and as a whole population

                     Hortega                   Pizarra                        Segovia                      Whole population
  ------------------ ------------------------- ------------------------------ ---------------------------- --------------------------
  N                  1502                      988                            1241                         3731
  Age (years)        54.4+19.3\*               46.1+13.9\*\*\*                51.9+10.8\*\*                51.4+15.9
  Height (m)         163.7+10.0\*              161+8.8                        161.4+9.0\*\*                162.2+9.4
  Weight (kg)        70.8+12.9\*               74.1+4.3\*\*\*                 72.1+12.4\*\*                72.1+13.2
  BMI kg/m^2^)       26.4+4.2\*                28.6+5.3\*\*\*                 27.7+4.3\*\*                 27.4+4.6
  Gender M(%)/F(%)   754 (50.2)/748 (49.8)\*   365 (36.9)/(616 (62.3)\*\*\*   562 (45.3)/(679 (54.7)\*\*   2043 (54.8)/(1681 (45.1)
  Obesity (N(%))     262 (17.4)\*              331 (33.5)\*\*\*               319 (25.7)\*\*               912 (24.4)

Values expressed as mean±SD except for gender and obesity. P value \<0.05 was considered significant. \*For p\<0.05 when comparing Hortega with Pizarra; \*\*p\<0.05 when comparing Hortega and Segovia; \*\*\* for p\<0.05 when comparing Pizarra and Segovia.

BMI, body mass index; F, female; M, male.

Association between MRC genes SNPs and obesity {#s3b}
----------------------------------------------

We performed the analysis looking for associations between SNPs, BMI and obesity risk in the three independent populations. [Table 2](#T2){ref-type="table"} shows results for SNPS with differences in at least one of the three populations and a similar trend in the remaining ones, or that had p values near the nominal cut-off point (p≤0.05) in the three studies: rs1136224 (*NDUFS2* gene), rs11205591 (*NDUFS5*), rs4600063 (*SDHC*), rs3770989 (*NDUFS1*) and rs10891319 (*SDHD*). These five SNPs were selected for further analysis in the whole population.

###### 

BMI and obesity risk of associated SNPs for Hortega, Pizarra and Segovia populations

               Genotype   HORTEGA   PIZARRA      SEGOVIA                                                                            
  ------------ ---------- --------- ------------ --------------------- ----- ------------ --------------------- ------ ------------ ---------------------
  *SDHC*       AA         1250      26.46±0.12   1                     772   28.70±0.19   1                     943    27.71±0.10   1
  rs4600063    AG-GG      183       26.16±0.30   0.82 (0.55 to 1.22)   96    27.86±0.04   0.47 (0.28 to 0.78)   132    27.21±0.30   0.88 (0.57 to 1.36)
  HWE: 1       P value              0.9          0.33                        0.071        **0.0025**                   0.22         0.57
  *NDUFS1*     TT         1308      26.41±0.12   1                     799   28.49±0.10   1                     1028   27.56±0.10   1
  rs3770989    CT-CC      114       26.62±0.44   1.13 (0.72 to 1.77)   77    29.85±0.60   1.5 (0.91 to 2.48)    65     27.92±0.60   1.28 (0.73 to 2.23)
  HWE: 1       P value              0.34         0.6                         **0.016**    0.12                         0.48         0.39
  *NDUFS2*     AA         1045      26.37±0.13   1                     640   28.61±0.21   1                     830    27.55±0.15   1
  rs1136224    AG-GG      369       26.59±0.23   1.43 (1.09 to 1.89)   223   28.59±0.34   1.10 (0.79 to 1.54)   241    27.77±0.26   1.07 (0.76 to 1.48)
  HWE: 0.36    P value              0.25         **0.011**                   0.71         0.58                         0.42         0.71
  *NDUFS5*     CC-CG      1309      26.47±0.12   1                     832   28.63±0.10   1                     947    27.6±0.14    1
  rs11205591   GG         115       25.78±0.31   0.67 (0.41 to 1.10)   38    27.66±0.70   0.86 (0.41 to 1.81)   89     27.21±0.40   0.89 (0.53 to 1.5)
  HWE: 0.76    P value              **0.049**    0.11                        0.38         0.69                         0.25         0.66
  *SDHD*       AA         691       26.16±0.16   1                     401   28.18±0.26   1                     571    27.37±0.17   1
  rs10891319   AG-GG      726       26.64±0.16   1.16 (0.90 to 1.49)   478   29.00±0.24   1.22 (0.91 to 1.64)   492    27.83±0.19   1.27 (0.96 to 1.68)
  HWE: 0.22    P value              0.08         0.25                        0.084        0.18                         0.077        0.095

BMI: mean±SD.

Bold: significant.

BMI, body mass index; HWE, Hardy-Weinberg equilibrium; N, number of individuals; SNP, single nucleotide polymorphism.

Analysing these five SNPS in the total population, four polymorphisms were associated with BMI: rs4600063, rs10891319, rs3770989, rs11205591, located in the *SDHC*, *SDHD*, *NDUFS1* and *NDUFS5*, genes, respectively. Results for these four SNPs are shown in [table 3](#T3){ref-type="table"}: rs4600063 and rs3770989 showed low association with BMI, which lost significance after Bonferroni correction (p\<0.0013). Rs10891319 and rs11205591 showed significant association with BMI after Bonferroni correction, with a p value of 0.0004 for the first one and 0.0011 for the second one. On the other hand, rs4600063 (genotypes AG and GG) and rs11205591 (GG genotype) reduced obesity risk, while rs10891319 (AG and GG genotypes) and rs1136224 (AG and GG genotypes) increased the risk (p\<0.05), but they did not reach the Bonferroni cut-off point.

###### 

SNP genotyping: distribution of BMI levels and the associated obesity risk for all genotypes in whole population

  --------------------------------------------------------------------------------------------------------------
  Gene/SNP         Genotype   N      BMI (kg/m^2^)   Non-obesity (N(%))   Obesity (N(%))   OR\
                                                                                           (95% CI)
  ---------------- ---------- ------ --------------- -------------------- ---------------- ---------------------
  *SDHC*           AA         2965   27.44±0.08      2109 (86.9)          851 (90.4)       1

  rs4600063        AG-GG      411    26.89±0.21      318 (13.1)           90 (9.6)         0.72 (0.56 to 0.92)

                   P value           **0.04**                                              **0.0072**

  *SDHD*           AA         1663   27.06±0.11      1243 (51.3)          422 (45.4)       1

  rs10891319       AG-GG      1696   27.60±0.11      1178 (48.7)          508 (54.6)       1.25 (1.08 to 1.46)

                   P value           **0.0004**                                            **0.0038**

  *NDUFS1*         TT         3135   27.32±0.08      2273 (92.9)          857 (91.2)       1

  rs3770989        CT-CC      256    27.92±0.32      173 (7.1)            83 (8.8)         1.30 (0.99 to 1.72)

                   P value           **0.026**                                             0.066

  *NDUFS2*         AA         2515   27.33±0.09      1833 (76.1)          680(73)          1

  rs1136224        AG-GG      833    27.46±0.16      575 (23.9)           251(27)          1.20 (1.01 to 1.43)

                   P value           0.31                                                  **0.041**

  *NDUFS5*         CC-CG      3088   27.40±0.08      2219 (92.3)          863(94)          1

  *rs11205591*\*   GG         242    26.60±0.24      184 (7.7)            55(6)            0.72 (0.52 to 0.99)

                   P value           **0.0011**                                            **0.039**
  --------------------------------------------------------------------------------------------------------------

Bold: significant, p\<0.05.

\*tag-SNP.

BMI values are expressed as mean±SD. Results after adjustment for the following variables included in the model: age and gender.

N, number of individuals; SNP, single nucleotide polymorphism.

[Figure 1](#F1){ref-type="fig"} shows BMI differences for rs10891319 and rs11205591 polymorphisms in each independent population and as a whole. A similar trend can be observed in both [figure 1A,B](#F1){ref-type="fig"}, although only the rs11205591 SNP reaches significance in the HORTEGA study (p[\<]{.ul}0.05).

![Body mass index (BMI) differences found for the associated single nucleotide polymorphism (SNPs) genotypes for each population analysed in this study. Values are expressed as BMI difference means, showing 95% CI. (A) rs10891319 BMI differences between AG-GG and AA genotypes, taking the first one (BMI difference=0 for carriers of AG-GG genotype) as reference. (B) rs11205591 BMI differences for CC-CG and GG genotypes, with the first one as a reference (CC-CG genotype BMI difference=0).](bmjopen-2018-027004f01){#F1}

We studied additive effects for all these SNPs and an additive effect for rs11205591 and rs10891319 SNPs was found in the whole sample: patients carrying GG/AA combination presented significant lower BMI ([figure 2A](#F2){ref-type="fig"}) and lower obesity risk ([figure 2B](#F2){ref-type="fig"}) than patients carrying CC-CG/AG GG genotypes (data are expressed as rs11205591 genotype/rs10891319 genotype).

![Additive effect of rs10891319 and rs11205591 genotype combination in body mas index (BMI) and obesity risk. (A) BMI means. \* indicates a p value \<0.005. (B) Obesity risk ORs. Rs11205591 CC-CG/rs10891319 AA genotypes were taken as a reference (OR=1). The obtained p value was \<0.003. Error bars show SE. Data are expressed as rs11205591/rs10891319 genotypes.](bmjopen-2018-027004f02){#F2}

On the other hand, some of the SNPs were within the gene. We calculated possible haplotypes, with negative results.

Discussion {#s4}
==========

The goal of this population-based study was to analyse MRC SNPs and their association with BMI and obesity risk in three Spanish populations. SNPs with the most relevant associations were tested in the pooled sample.

We found a significant protective association with the risk of obesity for rs10891319 AA, and for patients with the rs11205591 GG genotype, who also showed reduced BMI. Despite differences in age, sex, BMI and obesity prevalence between the three samples, a similar trend was found considering them individually, while rs10891319 showed the strongest in the whole sample. Furthermore, an additive interaction was observed between these two SNPs, with a maximal BMI difference of 1.4 kg/m2 found between genotypes (CC-GG/AA GG vs GG/AA carriers, expressed as rs11205591/rs10891319 genotype carriers). In agreement with these findings, significant differences in obesity risk were also found.

Another SNP associated with BMI in one of the three populations and in the whole group, rs3770989, is located in the 3'UTR region of the *NDUFS1* gene, which codes for NADH dehydrogenase (ubiquinone) Fe-S protein 1. In silico analysis in TargetScanHuman (<http://www.targetscan.org/vert_50/>) showed that this SNP is located between two regions of miRNA binding sites, although it does not seem to affect either of them.[@R30] On the other hand, the rs11205591 and rs10891319 SNPs are located in 3' regions of *NDUFS5* and *SDHD* genes, respectively. Although these SNPs have an unknown functional effect, they could be in linkage disequilibrium with other truly functional polymorphisms. New studies are needed to address this question.

The first gene consistently identified as an obesity gene using GWAS was FTO. Several SNPs located on its first intron were associated with BMI in European, East Asian and African populations.[@R32] Following this gene, 75 additional obesity loci have been identified using this methodology and, although FTO is the gene accounting for most of the interindividual variability on BMI, it only explains a 0.34%.[@R8] There are data supporting that alterations in genes related to mitochondrial function can be involved in obesity,[@R12] but few studies have analysed the effect of its variations on BMI or obesity.[@R19] From all genes identified in the GWAS meta-analysis performed by Speliotes and colleagues,[@R8] only the *NDUFS3* (NADH dehydrogenase (ubiquinone) Fe-S protein 3) gene was identified to be within 300 kb from the BMI-associated SNPs. As these authors indicated, in spite of the large population analysed in their study, many genetic variants related to BMI and obesity remain to be identified. The limitations of this meta-analysis come from the different microarrays used, with low coverage in many genomic regions. Therefore, the *NDUFS5* gene (where rs11205591 is located) has been analysed by only one polymorphism in each of the two most used microarrays by Speliotes and in most of the GWAS performed to date[@R8] (<http://www.Illumina.com>; <http://www.affymetrix.com>; <http://www.ensembl.org>). In addition, representation of Mediterranean populations in Speliotes and Locke's studies is very small, and, to our knowledge, Spanish populations are not included.[@R8] Therefore, many important genetic regions, related to BMI and obesity regulation in these populations, may be missing from their work.

The present study supports the hypothesis that genetic variations in MRC genes may be related to obesity susceptibility in the Spanish population. Therefore, these genes could be new therapeutic targets. Genetics of obesity are complex and not yet well identified, and our data may contribute to a better understanding. One limitation of this study is the reduced size of the analysed populations. However, the statistical power is sufficient for the number of analysed SNPs. On the other hand, we have not studied all the possible SNPs present in these MRC genes. Further functional studies and association analyses in larger samples and other populations should be carried out to confirm our results.
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